M-M-R II Shortage: What Providers and Prescribers Need to Know in 2026

The 2025 measles outbreak and subsequent surge in MMR vaccine demand have placed significant strain on commercial vaccine distribution channels. Many practices and pharmacies that provide M-M-R II (measles, mumps, and rubella virus vaccine live; Merck Sharp & Dohme) have encountered intermittent supply difficulties since early 2025. This briefing provides clinical guidance on navigating the shortage, counseling patients, managing substitutions, and maintaining immunization continuity for your panel.

Scope of the Current Supply Situation

As of 2026, there is no declared manufacturing shortage of M-M-R II. Merck has not issued a supply disruption notice, and the FDA has not added M-M-R II to its shortage database. However, demand-driven spot shortages at commercial pharmacy distributors have been widespread since the 2025 measles outbreak in Texas and New Mexico. Public-sector channels — including Vaccines for Children (VFC) program supply — have been less severely affected.

Research published in Nature Health (2026) identified areas with MMR coverage below 60% at the county level — significantly below the herd immunity threshold of approximately 95% for measles. These coverage gaps correlate with both the 2025 outbreak sites and ongoing high demand for catch-up vaccination.

PRIORIX as a Clinical Substitute: What You Need to Know

PRIORIX (GlaxoSmithKline) is FDA-approved and explicitly endorsed by the CDC as fully interchangeable with M-M-R II for all recommended indications. Key clinical equivalence points:

Indicated for prevention of measles, mumps, and rubella in individuals 12 months and older

Contraindications and precautions are the same as M-M-R II: pregnancy, immunosuppression, hypersensitivity to vaccine components, active febrile illness

Administration route: subcutaneous; same 0.5 mL dose

A patient who received dose 1 as M-M-R II may complete the series with PRIORIX — no series restart required

Billing: PRIORIX uses CPT code 90708 (vs. 90707 for M-M-R II); ensure your billing team updates code selection when PRIORIX is administered

ProQuad (MMRV) Considerations

ProQuad (Merck, MMRV) remains an option for children ages 12 months through 12 years who require both MMR and varicella vaccination. As a reminder:

When used as the first MMR/varicella dose in children 12-23 months, ProQuad carries a slightly elevated risk of febrile seizures (approximately 1 additional febrile seizure per 2,300 doses) compared to separate MMR + varicella vaccines

The CDC generally prefers separate MMR and varicella vaccines for the first dose in this age group; ProQuad is commonly used for the second dose (ages 4-6 years) without this concern

The VFC program updated its resolution in December 2025 to limit VFC-supplied MMRV (ProQuad) to children ages 4-12 years, reflecting the first-dose febrile seizure concern

VFC Program Supply: What Practices Should Know

Practices enrolled in the Vaccines for Children program have generally maintained more consistent MMR supply than commercial channels during the current shortage period. VFC-supplied vaccines are procured through state health departments rather than commercial distributors, providing partial insulation from demand-driven commercial shortages.

Key VFC reminders during shortage conditions:

VFC vaccines may only be administered to VFC-eligible patients (Medicaid-enrolled, uninsured, underinsured, or American Indian/Alaska Native children under 19)

Do not substitute VFC vaccines for privately purchased stock for non-eligible patients, even during a shortage — this is a VFC compliance violation

Contact your state VFC coordinator if supply is insufficient to maintain routine immunization schedules

Documentation Recommendations

Regardless of which product is administered, ensure your documentation captures:

Exact product administered (M-M-R II, PRIORIX, or ProQuad) — not just "MMR vaccine"

Lot number and manufacturer

Expiration date of the administered dose

Injection site and route

Vaccine Information Statement (VIS) given and publication date

Patient Counseling Talking Points

When counseling patients who are concerned about vaccine availability or the substitution of PRIORIX for M-M-R II, the following talking points are helpful:

"PRIORIX and M-M-R II are considered fully interchangeable by the CDC. You are getting the same protection with either vaccine."

"There is no national manufacturing shortage. The difficulty some patients have had finding the vaccine at commercial pharmacies is due to high demand, not a production problem."

"Delaying vaccination poses real risks. Measles spreads rapidly, and an unvaccinated person in a community with active cases faces significant exposure risk."

How medfinder Supports Your Patients

Patients who cannot find M-M-R II or PRIORIX at their usual pharmacy can use medfinder for providers to locate available stock. medfinder calls pharmacies near the patient's location, checks availability, and delivers results by text — reducing patient frustration and preventing delayed vaccination.

Also see our provider guide: How to Help Your Patients Find M-M-R II in Stock